FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Lorazepam Injection, USP
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Expand all

Akorn Pharmaceuticals (Revised 09/05/2018)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Lorazepam Injection 2 mg/mL (NDC 17478-040-01) Product available Demand increase for the drug

Amphastar Pharmaceuticals, Inc./IMS (Reverified 08/20/2018)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1) Available Other

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Reverified 10/04/2019)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25) Inventory is currently available. Additional lots are scheduled to be manufactured in the July - August 2019 timeframe. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the July - August 2019 timeframe. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Reverified 10/07/2019)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31) Next delivery: January 2020 Estimated Recovery: December 2020 Shortage per manufacturer: Manufacturing Delay Other
2 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1985-30) Available Other
2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02) Available Other
4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02) Available Other
20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English